24/7 Market News Snapshot 08 September, 2025 – Beyond Air, Inc. Common Stock (NASDAQ:XAIR)

September 8, 2025

DENVER, Colo., 08 September, 2025 (www.247marketnews.com) – (NASDAQ:XAIR) are discussed in this article.
Beyond Air, Inc. (NASDAQ:XAIR), a leader in medical devices and biopharmaceuticals focusing on innovative nitric oxide therapies, has recently achieved a significant stock market milestone. The company’s stock opened the trading day at $3.215, experiencing an impressive surge to $3.235—an increase of approximately 46.4% from the previous session’s close at $2.210. Amid a substantial trading volume of 168.14 million shares, this heightened activity indicates a strong bullish sentiment among investors, highlighting the company’s potential for further growth.

In conjunction with this market momentum, Beyond Air announced a strategic financial maneuver aimed at bolstering its capital structure. The company has entered into a definitive agreement for the immediate exercise of certain common warrants, leading to an anticipated issuance of up to 1,439,126 shares at a reduced exercise price of $2.21. This transaction is projected to generate approximately $3.25 million in gross proceeds and includes the issuance of new unregistered warrants for an additional 719,561 shares.

“We are excited to leverage this opportunity to strengthen our balance sheet and accelerate the development of our cutting-edge therapeutic solutions,” noted a spokesperson from Beyond Air. These funds will support the advancement of clinical trials targeting respiratory illnesses and neurological disorders alongside maintaining ongoing operational needs. The offering is being facilitated by Laidlaw & Company (UK) Ltd. as the exclusive placement agent and is expected to close shortly.

Beyond Air continues to be at the forefront of nitric oxide therapy with the FDA-approved LungFit® PH system, transforming the care of neonates with hypoxic respiratory failure. The company’s commitment to advancing various innovative LungFit systems through clinical trials reflects its dedication to improving patient outcomes across challenging health conditions, including severe lung infections and research initiatives addressing Autism Spectrum Disorder and cancer treatment.

Related news for (XAIR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.